VRN 11
Alternative Names: VRN-11; VRN-110755Latest Information Update: 06 Jun 2025
At a glance
- Originator Voronoi
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from a phase-I trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 16 Jan 2024 Phase-I clinical trials in Non-small cell lung cancer in South Korea (PO) prior to January 2024 (Voronoi pipeline, January 2024)